Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers-Reference-Cited by-同舟云学术

Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers

Published:2022-01 Issue: Volume:29 Page:107327482211062
ISSN:1073-2748
Container-title:Cancer Control
language:en
Short-container-title:Cancer Control

Author:

Rizzo Alessandro¹^ORCID,Cusmai Antonio¹,Massafra Raffaella²,Bove Samantha²,Comes Maria Colomba²,Fanizzi Annarita²,Gadaleta-Caldarola Gennaro³,Oreste Donato⁴,Zito Alfredo⁵,Giotta Francesco⁶,Lorusso Vito⁶,Palmiotti Gennaro¹

Affiliation:

1. Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello”, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco, Bari, Italy

2. Struttura Semplice Dipartimentale di Fisica Sanitaria, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco, Bari, Italy

3. Medical Oncology Unit, ‘Mons. R. Dimiccoli’ Hospital, Barletta, Azienda Sanitaria Locale Barletta, Italy

4. Radiology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Tumori Giovanni Paolo II, Bari, Italy

5. Unità Operativa Complessa di Anatomia Patologica, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco, Bari, Italy

6. Unità Operativa Complessa di Oncologia Medica, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco, Bari, Italy

Abstract

Epidermal growth factor receptor 2 (EGFR2, also known as HER2) overexpression and/or amplification confers a more aggressive clinical behavior but also represents a therapeutic opportunity for targeted therapies in breast cancer (BC). Over the last 2 decades, the prognosis of HER2-positive metastatic BC patients has improved due to the introduction of anti-HER2 agents including trastuzumab and novel, emerging drugs and combinations such as trastuzumab deruxtecan and tucatinib – trastuzumab - capecitabine. Herein, we provide a critical overview of current clinical recommendations and emerging treatment options for metastatic HER2-positive BC, especially focusing on recently presented and published clinical trials in this setting.

Publisher

SAGE Publications

Subject

Oncology,Hematology,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/10732748221106267

Reference39 articles.

1. Comprehensive molecular portraits of human breast tumours

2. The molecular diversity of Luminal A breast tumors

3. Breast cancer

4. Breast Cancer: Current Molecular Therapeutic Targets and New Players